1498 Stock Overview
An investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
PuraPharm Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.74 |
| 52 Week High | HK$1.26 |
| 52 Week Low | HK$0.67 |
| Beta | 0.24 |
| 11 Month Change | -2.63% |
| 3 Month Change | -5.13% |
| 1 Year Change | -25.25% |
| 33 Year Change | 5.71% |
| 5 Year Change | -63.55% |
| Change since IPO | -80.68% |
Recent News & Updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)
Feb 06
Is PuraPharm (HKG:1498) A Risky Investment?
Sep 28PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?
Nov 02Is PuraPharm (HKG:1498) A Risky Investment?
Aug 23PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues
Apr 01How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?
Dec 27
Shareholder Returns
| 1498 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | 2.7% |
| 1Y | -25.3% | -3.4% | 2.1% |
Return vs Industry: 1498 underperformed the Hong Kong Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: 1498 underperformed the Hong Kong Market which returned 2.1% over the past year.
Price Volatility
| 1498 volatility | |
|---|---|
| 1498 Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in HK Market | 15.3% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 1498 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1498's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 662 | Abraham Chan | www.purapharm.com |
PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names.
PuraPharm Corporation Limited Fundamentals Summary
| 1498 fundamental statistics | |
|---|---|
| Market cap | HK$292.34m |
| Earnings (TTM) | -HK$106.08m |
| Revenue (TTM) | HK$406.86m |
0.7x
P/S Ratio-2.8x
P/E RatioIs 1498 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1498 income statement (TTM) | |
|---|---|
| Revenue | HK$406.86m |
| Cost of Revenue | HK$190.23m |
| Gross Profit | HK$216.63m |
| Other Expenses | HK$322.71m |
| Earnings | -HK$106.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 53.24% |
| Net Profit Margin | -26.07% |
| Debt/Equity Ratio | 251.3% |
How did 1498 perform over the long term?
See historical performance and comparison